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Abstract
Autoimmune thyroid disease (AITD) is the most common organ-specific autoimmune disorder. AITD development occurs due to loss of 
immune tolerance and reactivity to thyroid autoantigens: thyroid peroxidase (TPO), thyroglobulin (TG) and thyroid stimulating hormone 
receptor (TSHR). This leads to infiltration of the gland by T cells and B cells that produce antibodies specific for clinical manifestations 
of hyperthyroidism in Graves’ disease (GD) and chronic autoimmune thyroiditis (cAIT). In addition, T cells in Hashimoto’s thyroiditis 
induce apoptosis in thyroid follicular cells, leading ultimately to the destruction of the gland. Cytokines are involved in the pathogen-
esis of thyroid diseases working in both the immune system and directly targeting the thyroid follicular cells. They are involved in the 
induction and effector phase of the immune response and inflammation, playing a key role in the pathogenesis of autoimmune thyroid 
disease. The presence of multiple cytokines has been demonstrated: IL-1a, IL-1b, IL-2, IL-4 , IL-6, IL-8, IL-10, IL-12, IL-13, IL-14, TNF-a 
and IFN-g within the inflammatory cells and thyroid follicular cells. Finally, cytokines derived from T cells can directly damage thyroid 
cells, leading to functional disorders and may also stimulate the production of nitric oxide (NO) and prostaglandin (PG), thus increasing 
the inflammatory response in AITD. 
Immunological mechanisms involved in the pathogenesis of AITD are strongly related to each other, but differences in the image of cAIT 
and GD phenotype are possibly due to a different type of immune response observed in these two counteracting clinical thyroid diseases. 
This article describes the potential role of cytokines and immune mechanisms in the pathogenesis of AITD. (Endokrynol Pol 2014; 65 (2): 150–155)
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Streszczenie
Autoimmunologiczna choroba tarczycy (AITD) jest najczęściej spotykaną narządowo-specyficzną chorobą autoimmunologiczną. Rozwój 
AITD następuje w wyniku utraty tolerancji immunologicznej i reaktywności na autoantygeny tarczycy: peroksydazę tarczycową (TPO), 
tyreoglobulinę (TG) i receptor tyreotropiny (TSHR ). Doprowadza to do infiltracji gruczołu przez limfocyty T oraz limfocyty B, które 
z kolei produkują charakterystyczne przeciwciała, z kliniczną manifestacją nadczynności tarczycy w chorobie Gravesa-Basedowa (GD) 
i niedoczynności tarczycy w przewlekłym autoimmunologicznym zapaleniu tarczycy (cAIT). Ponadto, w cAIT limfocyty T indukują 
apoptozę komórek pęcherzykowych tarczycy, prowadząc w konsekwencji do destrukcji gruczołu.
Cytokiny biorące udział w patomechanizmie chorób tarczycy działają zarówno na układ immunologiczny jak i bezpośrednio na docelowe 
komórki pęcherzykowe tarczycy. Uczestniczą w indukcji oraz w fazie efektorowej odpowiedzi immunologicznej i zapalnej, odgrywając 
kluczową rolę w patomechanizmie autoimmunologicznej choroby tarczycy. Zarówno w obrębie komórek zapalnych, jak i komórek 
pęcherzykowych tarczycy wykazano obecność wielu cytokin: IL-1a, IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-13, IL-14, TNF-a i IFN-g.
Ostatecznie, cytokiny wywodzące się z limfocytów T mogą bezpośrednio uszkadzać komórki tarczycy, prowadząc do zaburzeń funkcji 
tarczycy oraz mogą również stymulować produkcję tlenku azotu (NO) i prostaglandyn (PG), zwiększając reakcję zapalną w AITD.
Mechanizmy immunologiczne zaangażowane w patogenezie AITD są mocno ze sobą powiązane, jakkolwiek skutkują różnicą w obrazie 
fenotypowym cAIT i GD, prawdopodobnie z powodu swoistego rodzaju odpowiedzi immunologicznej obserwowanej w obu przeciwstaw-
nych klinicznie chorobach tarczycy. W niniejszym artykule przedstawiono potencjalną rolę cytokin i mechanizmów immunologicznych 
w patogenezie AITD. (Endokrynol Pol 2014; 65 (2): 150–155)
Słowa kluczowe: tarczyca; autoimmunologiczna choroba tarczycy; przeciwciała przeciwtarczycowe; limfocyty T; cytokiny
The immune system and autoimmune 
thyroid disease
Autoimmune thyroid dysfunction forms a clinical pic-
ture in which Graves’ disease (GD), characterised by hy-
perthyroidism, is at one pole, and chronic autoimmune 
thyroiditis (cAIT), manifested by hypothyroidism, is at 
the opposite one. 
Antibodies against thyroid antigens are present in 
both these diseases, but their specific epitopes are dif-
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ferent, resulting in different functional antibodies. AITD 
development occurs due to loss of immune tolerance 
to autoantigens and reactivity of the thyroid, which 
leads to infiltration of the gland by T cells and B cells, 
which in turn produce antibodies specific for clinical 
manifestations of hyperthyroidism and hypothyroid-
ism, GD and cAIT, respectively. Moreover, T cells in cAIT 
induce apoptosis in thyroid follicular cells, leading to 
the destruction of the gland [1, 2].
Antigen-presenting cells (APCs) or accessory cells, 
belonging to major histocompatibility complex (MHC) 
class II, especially dendritic cells, accumulate within the 
thyroid gland. APCs present specific thyroid antigens 
to lymphocytes within the lymph nodes, which leads 
to activation and proliferation of autoreactive lympho-
cytes T and B. In this way, activated antigen-specific 
T-helper lymphocytes CD4+ induce the formation 
of cytotoxic CD8+ T cells, and activate B cells, that 
produce autoantibodies, creating ectopic prolifera-
tion centers. Gland infiltration by cytotoxic T cells is 
primarily responsible for the destruction of thyroid 
parenchyma [3, 4].
The presence of an immunologically competent cell 
subset with suppressive activity, preventing a poten-
tially harmful autoimmune response, is due to regula-
tory T cells CD4+CD25+ (Treg). Lack of T regulatory 
cells in humans and mice results in the development 
of a number of systemic autoimmune disorders such as 
thyroiditis, arthritis, gastritis, multiple sclerosis, inflam-
mation of the ovaries, and others [5, 6].
Currently, there are documented three different 
populations of CD4+ T lymphocytes: Th1, Th2, and 
Th17. The development and differentiation of native 
CD4+ Th cells in populations diagnosing antigen is 
preceded, in cooperation with MHC class II signalling, 
by dendritic cells DC, with toll receptors - similar (TLRs) 
and C-type lectin receptors (CLR). The development 
of Th1 cells is dependent on IL-12, Th2 cells from IL-4, 
Th17 cells by TGF-b and IL-6 [7].
Th1 cells produce pro-inflammatory cytokines IL-
2, IFN-g, TNF, IL-1b, which leads to the activation of 
macrophages and cytotoxic effects. Th2 cells produce 
IL-4, IL-5, IL-6, IL-10, IL-13, which can inhibit the pro-
duction of Th1 cytokines, but primarily stimulate B cells 
to produce antibodies and activation of anti-apoptotic 
molecules [8].
Hashimoto’s thyroiditis (HT), a hyperplastic sub-
type of cAIT, is predominantly Th1 immune response, 
favouring the development of cell-mediated immu-
nity, and thyroid follicular cell death by apoptosis 
[9, 10]. Proapoptotic death ligands and receptors, 
such as TNF, FasL and TRAIL present on thyroid 
cells, under physiological conditions are inactive 
[9]. However, expression of the Fas/FasL-induced 
in response to pro-inflammatory Th1 cytokines by 
infiltrating IFN-g TNF and IL-1b activates thyroid 
cell apoptosis [11–13].
The GD promotes Th2 predominantly humoral 
response, increased production of antibodies by B cells 
increases concentration of immunoglobulin G (IgG) and 
the cytokines produced by Th2 cells, which promote 
humoral response, thus inhibiting the expression of 
Fas/FasL and results in activation of the anti-apoptotic 
molecule Bcl-2, that protects thyrocytes from apoptosis, 
but increases apoptosis of cytotoxic lymphocytes, infil-
trating thyroid tissue [10, 12]. Schematic pathogenesis 
of AITD illustrates the diagram in Figure 1.
A new subtype of Th17 response may also be 
involved in the pathogenesis of GD [14]. Th17 cells, 
which have been described recently, secrete proin-
flammatory cytokines (IL-17, IL-17F, IL-21, IL-22) 
and play an important role in chronic inflammatory 
diseases such as asthma and systemic lupus erythe-
matosus [15]. The percentage of Th17 cells in patients 
Figure 1. Pathogenesis of chronic autoimmune thyroiditis (cAIT) 
and Graves’ disease (GD)
Rycina 1. Patogeneza przewlekłego autoimmunologicznego 
zapalenia tarczycy (cAIT) i choroby Gravesa-Basedowa (GD)
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with GD was first described by Nanba et al., showing 
a higher rate of Th17 lymphocytes in patients not 
treated with anti-thyroid drugs, compared to remis-
sion in patients with GD [16]. 
Study profile of Th17 cells in HT revealed increased 
expression of the gene RORC2 responsible for the 
differentiation subpopulation Th17 phenotype, and 
increased number of Th17 cells in peripheral blood 
and thyroid tissue in patients with HT, without proof of 
a similar situation in patients with GD [17]. Similar 
observations have been made by Idzkowska and 
Bossowski among children with newly diagnosed HT, 
to yield a statistically significant elevated levels of IL-17 
and IL-23, which supports the participation of the Th17 
in the pathogenesis of HT [18].
Extracellular mechanism of peripheral tolerance is 
mediated by regulatory T cells CD4+CD25+, mainly 
type 1 (Tr1). T regulatory cells were first described in 
the 1970s and 80s, when they were called suppressor 
cells. Recent studies have shown the importance of 
the key T lymphocytes CD4+CD25+ cells in the im-
mune response, in which the suppressor mechanism 
of action is based on direct effect on thyroid follicular 
cells. It is assumed now that all T regulatory cells are 
characterised by expression of the transcription factor 
Foxp3, which is an essential element in the develop-
ment and functioning. Regulatory T cells play an 
important role in disorders of immune tolerance to 
self antigens. Deficiency and impaired function of 
these cells may be the cause of autoimmune thyroid 
disease. Nakano et al. found that the percentage of 
regulatory T cells within the thyroid lymphocyte 
cells was lower in patients with autoimmune thyroid 
disease [19, 20]. 
In human and mouse T lymphocytes, CD4+CD25+ 
represent about 5-10% of the population of CD4+ T 
lymphocytes. Regulatory T cells mediate suppression 
mechanisms, by inhibiting IL-2 secretion and the secre-
tion of anti-inflammatory cytokines, such as IL-4, IL-10, 
and TGF-b. Thus the action of T regulatory lymphocytes 
inhibits and modulates immune response Th1, Th2 and 
Th17 [21, 22].
Therefore, the clinical manifestation of autoim-
mune thyroid phenotype in the direction to GD 
and cAIT largely depends on the balance of the 
immune response induced Th1 or Th2 by the APCs, 
and the cytokine profile, which dominates at this 
point in thyroid parenchyma. The fact that these 
two functionally opposite states can develop in the 
same person at different periods suggests that the 
Th1/Th2 balance and the related cytokine profile is 
a dynamic process, evolving under the influence of 
external factors operating in the local environment 
of the thyroid gland [23, 24].
The participation of antibodies  
in the pathogenesis of AITD
Autoimmune thyroid disease is an autoimmune disease 
that affects approximately 5% of the population and is 
the most common organ-specific autoimmune disease. 
Activated B cells secrete antibodies directed against sev-
eral major thyroid antigens. The occurrence of autoan-
tibodies is characteristic of the disease, although these 
antibodies are also found in healthy individuals [25].
Anti-thyroid antibodies (ATG, ATPO)
Thyroid peroxidase antibodies (ATPO) are a marker 
of autoimmune thyroid disease. ATPO are present in 
nearly all patients with Hashimoto’s thyroiditis, in two 
thirds of patients with postpartum thyroiditis, and in 
75% of patients with hyperthyroidism in the course of 
Graves’ disease. Thyroid peroxidase is a key enzyme 
involved in thyroid hormonogenesis. This antigen 
was identified in 1959 as the thyroid microsomal an-
tigen. ATPO levels are associated with the expression 
of MHC on thyrocytes and with degree of infiltration 
by lymphocytes, which may ‘sensitise’ and trigger the 
synthesis of autoantibodies [26, 27].
Antibodies are produced mainly by lymphocytes 
infiltrating the thyroid gland, and only to a small ex-
tent by the local lymph nodes or bone marrow. It turns 
out that the presence of gammaglobulin antibodies is 
ascertained in 12–26% of asymptomatic patients with 
thyroid disease and is a risk factor for the future onset 
of hypothyroidism. Anti-TPO antibodies, in contrast 
to anti-thyroglobulin antibodies (ATG), are able to in-
duce the complement system and cellular cytotoxicity. 
There is a high correlation between the concentration 
of anti-thyroid peroxidase antibodies and the presence 
of lymphocytic infiltration of the thyroid gland [28, 29].
ATPO are polyclonal, heterogeneous and directed 
towards different parts of TPO molecules, most of 
which recognise epitopes located on the surface of 
the enzyme TPO. Two major conformational immu-
nomodulatory A and B regions (IDR-A and IDR-B) on 
the surface of the TPO are of particular importance, 
since they are in close proximity or even overlap each 
other [30]. Studies have shown that antibodies to the 
IDR-B domain are confirmed in most patients with HT 
and GD [31].
ATPO are also present in 12–16% of euthyroid patients, 
in 20% of type 1 diabetics and also in other autoimmune 
diseases: Addison’s disease — 50%, rheumatoid arthri-
tis — 30%, Sjogren’s syndrome — 17–40%, SLE — 23%, 
scleroderma — 19%, and fibromyalgia — 24% [27].
In the NHANES III study population, the incidence 
of ATPO in the United States in healthy Caucasians 
was 12.3%. It was similar in the population of Mexican 
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origin — 10.1%, but significantly lower among African-
Americans — 4.5%. Female gender is associated with 
a 2–4-fold higher incidence of ATPO. The percentage 
of antibodies increases with age for both sexes to al-
most 30% in chronically ill elderly patients. Antibodies 
against thyroglobulin are present in 97% of patients 
with Hashimoto’s thyroiditis, and about 50% of cases of 
Graves’ disease and in 10–20% of patients with subacute 
thyroiditis (de Quervaine’s disease)[32].
In a multicentre study performed in 2007–2010 in 
Poland (PolSenior), in age groups ranging from 65 to 90 
years of age, increased ATPO was revealed in 19% of 
the cohort. Prevalence of ATPO positivity was higher 
in females than in males (26.6% v.15.5%). Among 1,542 
subjects with known concentrations of both ATPO 
and thyroid function, 1,110 were euthyroid (72%), 317 
hypothyroid (20.6%), and 115 hyperthyroid (7.4%) [33].
Thyrotropin receptor antibodies (TRAb)
TSH receptor antibodies (TRAb) mimic the function of 
TSH and cause disease by binding to the TSH receptor 
and stimulate or inhibit thyroid cells in terms of T3 and 
T4 production. Patients with AIT may present both 
stimulating and blocking antibodies. The clinical picture 
of the disease is a result of the relative strength of each 
antibody type. While Graves’ disease is characterised 
by the production of stimulating autoantibodies TSHR-
TSAb, another group of patients with autoimmune 
thyroid disease may have autoantibodies that block the 
activation of TSHR-TBAb [34, 35]
The determination of concentrations of TRAb is helpful 
in the differential diagnosis of hyperthyroidism, Graves’ 
disease, autoimmune disease aetiology and in predicting 
relapse after anti-thyroid drug treatment. Patients with 
high levels of TRAb (> 10 IU/L) have a 8.7 to 31.1 times 
higher risk of severe course of GO, and are likely to relapse 
after initial treatment with anti-thyroid drugs [35].
Currently, the detection of TRAb antibodies is 
widely used in Europe and Japan, the second and third 
generation of competitive tests TBII were developed for 
the first time by Smith et al [36]. However, this test does 
not differentiate the biological activity of the antibod-
ies, TSAb and TBAb, which is possible using a bioassay 
based on cell culture and recombinant human TSHR, 
but is limited due to much efforts and costs. Second-
generation TBII tests have 100% specificity and 98% 
diagnostic sensitivity [37–39]. 
Participation of cytokines in the pathogenesis 
of autoimmune thyroid disease
Cytokines are glycoproteins released by activated 
cells from different tissues. They provide a network 
control system of many processes such as prolifera-
tion, differentiation, secretion of biologically important 
substances. They play a key role in modulating the 
immune response and influence the balance between 
maintaining tolerance and initiating autoimmunity. In 
addition to hormone-like properties, they are involved 
in the process of haematopoesis, affect the functions of 
other cells and are mediators of inflammation and im-
mune response, repair processes and wound healing.
Cytokines are involved in the pathogenesis of 
thyroid diseases, working in both the immune system 
and directly targeting the thyroid follicular cells. They 
participate in the induction and effector phase of the 
immune response and inflammation and play a key role 
in the pathogenesis of autoimmune thyroid disease, 
including cAIT and Graves’ disease. Within the inflam-
matory cells and thyroid follicular cells, the presence of 
multiple cytokines: IL-1a, IL-1b, IL-2, IL-4, IL-6, IL-8, 
IL-10, IL-12, IL-13, IL-14, TNF-a and IFN-g has been 
demonstrated [40, 41].
Cytokines in cytokine network play different func-
tions: some effects are promoted by cytokines and 
inhibited by others. Cytokine secretion profile can be 
considered as a pro-inflammatory or anti-inflammatory, 
pro-apoptotic or anti-apoptotic. Under the influence of 
chronic antigen challenge, macrophages and CD4+ T 
cells can be divided into cells Th1 producing cytokines 
involved in the cellular response (IL-2, IFN-g, TNF-a, 
IL-1b), or subpopulations of Th2 lymphocytes, which 
secrete cytokines associated with humoral response 
(IL-4, IL-5, IL-6, IL-10, IL-13), and Th17 producing IL-
17, IL-21, IL-22. Th3 immune cells produce mainly TGF 
and play an important role in protecting against the 
occurrence of autoimmune diseases [42–44]. Despite 
attempts to classify autoimmune thyroid disease as a 
classical Th1- or Th2-dependent, there is mixed Th1/Th2 
immune response in both HT and in GD [16].
Cytokines are produced by both lymphocytes and 
thyroid follicular cells. Experiments conducted in vitro 
have confirmed the production of cytokines by the 
stimulation of thyroid follicular cells by IL-1, IFN-g 
and TNF-a, suggesting an increase of activity and an 
increased infiltration of pro-inflammatory cells in vivo. 
These cytokines increase the expression of adhesion 
molecules on the surface of thyroid follicular cells, and 
may also stimulate production of nitric oxide (NO) 
and prostaglandin (PG), increasing the inflammatory 
response in AITD. Thyroid tissue cytokines also play 
a role in antigen presentation to T cells by increasing 
the expression of MHC class I and II on the surface of 
the thyroid follicular cells, leading to destruction of the 
thyroid gland by T cell cytotoxicity. In thyroid ophthal-
mopathy, pathogenic action of cytokines: IL-b, TNF-a 
and IFN-g, exacerbate inflammation and proliferation 
of fibroblasts, resulting in the accumulation of glycos-
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aminoglycans within the orbit. In Graves’ disease, IL-1b 
stimulates the production of hyaluronic acid in thyroid 
epithelial cells and fibroblasts, thus contributing to the 
development of the goitre [45–48]. 
On the basis of thyroid tissue immunohistochemis-
try, the presence of IFN-g in cells infiltrating the thyroid 
gland, IL-1 in endothelial thyroid cells, and increased 
the amount of IL-1, IL-6 and TNF-a in thyroid follicular 
cells was revealed. In cell cultures, IL-1 and IL-6 increase 
the proliferation of the thyroid follicular cells, but also 
have inhibitory effects on thyrocytes during stimulation 
of these cells by TSH [49].
Cytokines in many cases exhibit a pleiotropic action 
and often may function as both an immunostimula-
tory and an immunosuppressive agent, depending on 
the type and location of the target. For example, the 
cytokine IL-2, IFN-g and TNF-a activity may exhibit 
both inhibitory and excitatory function in autoimmune 
diseases [50]. 
IFN-g and TNF-a inhibit the growth and prolifera-
tion of the thyroid follicular cells, but do not affect the 
viability of cells [49]. Pro-inflammatory cytokines such 
as IL-1b, IL-6 and TNF-a are generally associated with 
the stimulation of inflammation and autoimmunity, 
and may also stimulate production of T regulatory 
lymphocytes, inhibiting development of autoimmune 
diseases [51]. 
Cytokines enhance the inflammatory response by 
stimulation of both T and B lymphocytes, resulting in 
the production of antibodies and thyroid tissue damage 
by apoptosis, in particular in HT [52]. Cytokines can 
modulate the growth and function of thyroid follicular 
cells themselves in AITD, playing an important role 
in the extra-thyroid AITD complications, particularly 
ophthalmopathy. Exogenous administration of cyto-
kines such as IFN-a is associated with the appearance 
of autoimmune thyroid disorders and the emergence of 
antibodies ATPO and ATG [40]. Krupinska et al. report-
ed an elevated concentration of antithyroid antibodies 
in 17.14% of patients, with no signs of AIT at baseline, 
detected during therapy with interferon, after six and 
12 months of treatment. After six months of treatment 
in this group of patients, 11 had hypothyroidsm and 
six had hyperthyroidism [53].
Conclusions
The role of cytokines in the development of autoim-
mune thyroid disease and their participation in the pro-
cesses leading to the development of hypothyroidism in 
chronic autoimmune thyroiditis and hyperthyroidism 
in Graves’ disease is still not clear. The demonstration 
of immune cells and anti-thyroid antibodies within the 
thyroid gland, and the determination of the levels of cy-
tokines in peripheral blood, provide information about 
their involvement in the pathogenesis of AITD. These 
observations serve to confirm the effect of cytokines 
and their important role in maintaining the balance 
between health and disease.
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